COMBINATION THERAPY WITH TARGETED OX40 AGONISTS

The present invention relates to combination therapies employing tumor targeted bispecific OX40 antibodies, in particular anti-FAP/anti-OX40 antibodies in combination with T-cell activating anti-CD3 bispecific antibodies specific for a tumor-associated antigen, the use of these combination therapies...

Full description

Saved in:
Bibliographic Details
Main Authors BACAC, Marina, PINCHA, Mudita, SAM, Johannes, GRAU-RICHARDS, Sandra, UMANA, Pablo, KLEIN, Christian, LANG, Sabine, AMANN, Maria
Format Patent
LanguageEnglish
French
Published 09.05.2019
Subjects
CHEMISTRY
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to combination therapies employing tumor targeted bispecific OX40 antibodies, in particular anti-FAP/anti-OX40 antibodies in combination with T-cell activating anti-CD3 bispecific antibodies specific for a tumor-associated antigen, the use of these combination therapies for the treatment of cancer and methods of using the combination therapies. La présente invention concerne des polythérapies utilisant des anticorps OX40 bispécifiques ciblant des tumeurs, en particulier des anticorps anti-FAP/anti-OX40 en combinaison avec des anticorps bispécifiques anti-CD3 activant des lymphocytes T spécifiques d'un antigène associé à une tumeur, l'utilisation de ces polythérapies pour le traitement du cancer et des procédés d'utilisation des polythérapies.
Bibliography:Application Number: WO2018EP79781